The Europe Omics Lab Services Market would witness market growth of 12.5% CAGR during the forecast period (2022-2028).
A thorough understanding of the molecules which make up a cell, tissue, or organism is provided through omics technology. They are largely focused on the non-targeted, non-biased detection of all genes (genomics), proteins (proteomics), mRNA (transcriptomics), and metabolites (metabolomics) in a particular biological sample. The combination of these methodologies is known as system biology, and this may also be referred to as advanced biology.
Experiments in systems biology and omics are distinct from conventional investigations, which are mostly hypothesis-driven. While no hypothesis is specified or mandated in systems biology studies, all data are collected and evaluated to produce a hypothesis that may be tested further. These experiments use holistic methodologies instead. Omics technology may be used to better understand not just physiological processes that occur naturally but also those that occur in illness, where it can be used for prognostication, diagnosis, and screening. It can also be used to better understand the genesis of diseases.
For the study of the transcriptome, many techniques, including microarrays, real-time polymerase chain reaction, RNA sequencing, RNA interference, SAGE, expressed sequence tag (EST)-based technologies, and others, have been developed.
Lung cancer is the leading cause of mortality in Europe, responsible for roughly 20% of all cancer deaths and 3.2 million disability-adjusted life years lost each year. Lung cancer affects more than a quarter of those under the age of 60. Seven out of every eight patients die after five years of diagnosis, given current breakthroughs in surgery, chemotherapy, and radiotherapy. New findings in knowing the biology of lung cancer, on the other hand, have resulted in the development of potential novel targeted medicines.
The Germany market dominated the Europe Omics Lab Services Market by Country in 2021; thereby, achieving a market value of $9.2 billion by 2028. The UK market is exhibiting a CAGR of 11.5% during (2022 - 2028). Additionally, The France market would experience a CAGR of 13.3% during (2022 - 2028).
Based on Business, the market is segmented into Diagnostic Labs, Research Institutes, and Hospitals. Based on End Use, the market is segmented into Cancer, Pharmaco, Population Studies & Genealogy, Reproductive, Skincare, Nutrition, Vitamin & Supplements, and Forensics & Others. Based on Type, the market is segmented into Proteomics, Transcriptomic, Metabolomics, Genomics, and Epigenetics. Based on Product, the market is segmented into Hardware Equipment, Testing / Lab Services, and Analytics / Interpretation. Based on Frequency of Service, the market is segmented into Continuous, Repeat, and One-off. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Omics Lab Services Market will Hit $139.1 Billion by 2028, at a CAGR of 12.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Illumina, Inc., BGI Group, Q2 Solutions (IQVIA), Flomics Biotech, PhenoSwitch Bioscience
By Business
By End-Use
By Type
By Product
By Frequency of Service
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
